Adoptive immunotherapy

Current Opinion in Oncology

Volumn 9, Issue 6, 1997, Pages 579-583

  Ballen, Karen ^a   Stewart, F Marc ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ALLOGENIC BONE MARROW TRANSPLANTATION; BRAIN TUMOR; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; EPSTEIN BARR VIRUS; HUMAN; IMMUNOCOMPETENT CELL; KIDNEY CARCINOMA; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MELANOMA; META ANALYSIS; PRIORITY JOURNAL; RELAPSE; REVIEW; SOLID TUMOR; SURVIVAL RATE;

EID: 0030838181     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199711000-00014     Document Type: Review

References (28)

1. Billingham RE, Brent L, Medowar PB: Quantitative studies on tissue transplantation. Proc R Soc Biol 1954, 143:58.
2. Arca MJ, Mule JJ, Chang AE: Genetic approaches to adoptive cellular therapy of malignancy. Semin Oncol 1996, 23(1):108-117 This manuscript reviews the genetic advances in the use of immunotherapy for cancer treatment.
3. Rosenberg SA, Lotze MT, Muul LM, et al.: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985, 313:1485-1492.
4. Giralt SA, Kolb HJ: Donor lymphocyte infusions. Curr Opin Oncol 1996, 8:96-102. This article reviews the use of lymphocyte infusions for CML and other diseases.
5. Kolb HJ, Shattenberg A, Goldman JM, Hugrenstein B, Jacobsenn RC, Ese W, Ljungman P, Ferrant A, Verdon CKL, Ninverwies ERD, et al.: Graft versus leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for Blood and Marrow Transplantation. Working Party of Chronic Leukemia. Blood 1995, 86:2041-2050.
6. Jones RJ: Biology and Treatment of chronic myeloid leukemia. Curr Opin Oncol 1997, 9:3-7. The advances in chronic myeloid leukemia, particularly the use of adoptive immunotherapy donor lymphocytes infusions, is reviewed.
7. Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EJ: Graft-versus-myeloma effect in two cases. Lancet 1996, 347:800-801. Two patients with recurrent multiple myeloma were successfully treated with donor lymphocytes after transplantation.
8. Bertz H, Burger JA, Kunzmann R, Mertelsmann R, Finke J: Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect Leukemia 1997, 11:281-283. The immunotherapy with multiple myeloma is reported in a single case with this review of the literature.
9. Porter DL, Roth MS, Lee SJ, McGairgle C, Ferrara JML, Antin JH: Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse rate of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996, 18:975-980. The use of donor lymphocyte infusion for relapse after transplantation is reviewed in patients with leukemia and myelodysplasia. The data are worse than that achieved in patients with CML.
10. Lucas KG, Small TN, Heller G, Dupont B, O'Reilly RJ: The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 1996, 87:2594-2603. A correlation is documented between low Epstein-Barr virus cytotoxic T lymphocyte precursors and the risk of posttransplantation Epstein-Barr virus lymphomas. A correlation between deficient EBV-specific T-cell immunity and development of posttransplantation lymphoproliferative disorder is also discussed.
11. O'Reilly RJ, Lacerda JF, Lucas KG, Rosenfield NS, Small TN, Papadopoulos EB: Adoptive cell therapy with donor lymphocytes for EBV-associated lymphomas developing after allogeneic marrow transplants. In Important Advances in Oncology. Edited by Vincent T. DeVita, Samuel Hellman, and Steven A. Rosenberg. Lippincott-Raven Publishers, Philadelphia; 1996:149-162.
12. Kohler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495.
13. Sondel PM, Hank JA, Kohier PC, Sosman JA, Weil-Hillman G, Fisch P: The cellular immunotherapy of cancer: current and potential uses of interleukin-2. Crit Rev Oncol Hematol 1989, 9:125.
14. Stewart FM, Crittenden RB, Lowry PA, Pearson-White S, Quesenberry PJ: Long-term engraftment of normal and post-5-fluorouracil murine marrow inro normal nonmyeloablated mice. Blood 1993, 10:2566-2571.
15. Giralt S, Estey E, Albitar M, vanBesien K, Rondon G, Anderlini P, O'Brien S, Khouri I, Gajewski J, et al.: Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997, 89:4531-4536. Minimally ablative therapy can be used successfully in older patients.
16. Kadota RP: Perspectives on investigational chemotherapy and biologic therapy for childhood brain tumors. J Pediatric Hematol Oncol 1996, 18(1):13-22.
17. Toso JF, Oei C, Oshidari F, Tartaglia J, Paoletti E, Lyerly HK, Talib S, Weinhold KJ: MAGE-1 specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation. Cancer Res 1996, 36:16-20.
18. Gratama JW, Schmitz PIM, Goey SH, Lamers CHJ, Stoter G, Bolhuis RLH: Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy, IFNα and autologous IL-2 activated lymphocytes. Int J Cancer 1996, 65:152-160. The addition of interferon to IL-2 and IL-2-activated lymphocytes may improve response in renal cell cancer.
19. Belldegrun A, Tso C-L, Kaboo R, Pang S, Pierce W, deKernion JB, Figlin R: Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2 based therapy. J Immunother 1996, 92:149-161. Clinical outcome largely dependent on pretransplantation immune status and natural killer cell activity of patient.
20. Wang R-F, Rosenberg SA: Human tumor antigens recognized by T lymphocytes: implications for cancer therapy. J Leuk Biol 1996, 60:296-306.
21. Conlon KC, Anver MR, Longo DL, Ortaldo JR, Murphy WJ: Adoptive immunotherapy involving recombinant human M-CSF and R24 antimelanoma antibody induces human T-cell infiltration into human melanoma xenografts. J Immunother 1996, 19:317-323. Human T cells can be targeted to specific tumor sites by antibiotics and cytokine treatment.
22. Elias EG, Suter CM, Fabian DS: Adjuvant immunotherapy in melanoma with irradiated autologous tumor cells and low dose cyclophosphamide. J Surg Oncol 1997, 64:17-22.
23. Melioli G, Ratto GB, Ponte M, Guastella M, Semino C, Fantino G, Tassara E, Pasquetti W, Mereu C, Merlo F, Reggiardo G, Morasso G, Santi L, Moretta L: Treatment of stage IIIB non-small-cell lung cancer with surgery followed by infusion of tumor infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Immunother 1996, 19:224-230. Infusion of TIL in lung cancer is feasible and may prolong survival.
24. Kimura H, Yamaguchi Y: Adjuvant chemo-immunotherapy after curative resection of stage II and IIIA primary lung cancer. Lung Cancer 1996, 14:301-314. Patients treated with combined chemotherapy and immunotherapy has a 53% 5-year survival rate.
25. Ratto GB, Zino P, Mirabellis S, Minuti P: A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected non-small cell lung carcinoma. Cancer 1996, 78:244-251 In a randomized study, stage IIIB patients treated with adoptive immunotherapy survived longer than control patients (22 months vs 7 months).
26. Karp DD, Atkins MB: Adoptive immunotherapy for nonsmall cell lung carcinoma. Cancer 1996, 78:195-198.
27. Haruta I, Yamauchi K, Aruga A, Komatsu T, Takasaki K, Hayashi N, Hany F: Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced hepatocellular carcinoma: comparison between LAK cell and CTL therapy. J Immunother 1996, 19:219-223. Tumor-specific CTL therapy is more effective than LAK therapy for advanced hepatocellular carcinoma.
28. Ikarashi H, Fujita K, Takakuwa K, Kodama F, Tokunaga A, Takashahi T, Tanaka K: Immunomodulation in patients with epithelial ovarian cancer for adoptive transfer of tumor-infiltrating lymphocytes. Cancer Res 1994, 54:190-196.